drugset / Trial / NCT00589784
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Phase 2
Completed
50 enrolled
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute · collabPfizer · collabUniversity of Pittsburgh · collabUniversity of Virginia · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, sunitinib has on patients and their tumors. At this time, no drugs are routinely used to treat meningioma, hemangioblastoma or hemangiopericytoma. Only surgery and radiation therapy are known to be useful. Sunitinib is a drug approved for advanced kidney cancer. Sunitinib is also being studied for other tumors. It may be useful in the treatment of brain tumors because it can prevent formation of new blood vessels that allow tumor cells to survive and grow.
Timeline
- Start
- 2007-10
- Primary completion
- 2014-10
- Completion
- 2014-10